It has been widely known that human epidermal growth factor receptor 2 (HER2) inhibitors exhibit distinct antitumor responses against HER2-positive breast cancer. To date, Lapatinib (Tykerb®) has been approved by the U.S. Food and Drug Administration (FDA) as a reversible HER2 inhibitor for treating breast cancer. However, HER2 L755S, T798I and T798M mutations confer drug resistance to lapatinib, restricting its efficacy toward HER2-positive breast cancer. Thus, novel therapy toward mutant HER2 is highly desired. Although several irreversible HER2 inhibitors have been developed to overcome these drug resistance problems, most of them were reported to cause severe side effects. In this study, three pharmacophore models based on HER2 L755S, T798I and T798M mutant structures were constructed and then validated through receiver operating characteristic (ROC) curve analysis and Güner-Henry (GH) scoring methods. Subsequently, these well-validated models were utilized as 3D queries to identify novel irreversible HER2 inhibitors from National Cancer Institute (NCI) database. Finally, two potential irreversible HER2 inhibitor candidates, NSC278329 and NSC718305, were identified and validated through molecular docking, molecular dynamics (MD) simulations and ADMET prediction. Furthermore, the analyses of binding modes showed that both NSC278329 and NSC718305 exhibit good binding interactions with HER2 L755S, T798I and T798M mutants. All together, the above results suggest that both NSC278329 and NSC718305 can serve as novel and effective irreversible HER2 inhibitors for treating breast cancers with HER2 L755S, T798I and T798M mutants. In addition, they may act as lead compounds for designing new irreversible HER2 inhibitors by carrying out structural modifications and optimizations in future studies.
References
[1]
Bellmunt, J., Werner, L., Bamias, A., Fay, A.P., Park, R.S., Riester, M., Selvarajah, S., Barletta, J.A., Berman, D.M., Muga, S.D., Salido, M., Gallardo, E., Rojo, F., Guancial, E.A., Bambury, R., Mullane, S.A., Choueiri, T.K., Loda, M., Stack, E. and Rosenberg, J. (2015) HER2 as a Target in Invasive Urothelial Carcinoma. Cancer Medicine, 4, 844-852. https://doi.org/10.1002/cam4.432
[2]
Logan, G.J., Dabbs, D.J., Lucas, P.C., et al. (2015) Molecular Drivers of Lobular Carcinoma in Situ. Breast Cancer Research, 17, 76. https://doi.org/10.1186/s13058-015-0580-5
[3]
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene. Science, 235, 177-182.
https://doi.org/10.1126/science.3798106
[4]
Brandt-Rauf, P.W., Pincus, M.R. and Carney, W.P. (1994) The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular Epidermal Epidemiology. Critical Reviews in Oncogenesis, 5, 313-329.
https://doi.org/10.1615/CritRevOncog.v5.i2-3.100
[5]
Sun, A., Shi, Y., Shen, Y., Cao, L., Zhang, W. and Guan, X. (2015) Analysis of Different HER-2 Mutations in Breast Cancer Progression and Drug Resistance. Journal of Cellular and Molecular Medicine, 19, 2691-2701.
https://doi.org/10.1111/jcmm.12662
[6]
Burris, H.A. (2004) Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib. The Oncologist, 9, 10-15. https://doi.org/10.1634/theoncologist.9-suppl_3-10
[7]
Minami, Y., Shimamura, T., Shah, K., La Framboise, T., Glatt, K.A., Liniker, E., et al. (2007) The Major Lung Cancer-Derived Mutants of ERBB2 Are Oncogenic and Are Associated with Sensitivity to the Irreversible EGFR/ERBB2 Inhibitor HKI-272. Oncogene, 26, 5023-5027. https://doi.org/10.1038/sj.onc.1210292
[8]
Kancha, R.K., Bubnoff, N.V., Bartosch, N., Peschel, C., Engh, R.A. and Duyster, J. (2011) Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib. PLoS ONE, 6, e26760.
https://doi.org/10.1371/journal.pone.0026760
[9]
Rexer, B.N., Ghosh, R., Narasanna, A., Estrada, M.V., Chakrabarty, A., Song, Y., Engelman, J.A. and Arteaga, C.L. (2013) Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2. American Association for Cancer Research, 19, 5390-5401. https://doi.org/10.1158/1078-0432.CCR-13-1038
[10]
Bose, R., Kavuri, S.M., Searleman, A.C., Shen, W., Shen, D., Koboldt, D.C., Monsey, J., Goel, N., Aronson, A.B., Li, S., Ma, C.X., Ding, L., Mardis, E.R. and Ellis, M.J. (2013) Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. Cancer Discovery, 3, 224-237. https://doi.org/10.1158/2159-8290.CD-12-0349
[11]
Mishra, R., Hanker, A.B. and Garrett, J.T. (2017) Genomic Alterations of ERBB Receptors in Cancer: Clinical Implications. Oncotarget, 8, 114371-114392. https://doi.org/10.18632/oncotarget.22825
[12]
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L.R., Padera, R.F., Shapiro, G.I., Baum, A., Himmelsbach, F., Rettig, W.J., Meyerson, M., Solca, F., Greulich, H. and Wong, K.K. (2008) BIBW2992, an Irreversible EGFR/HER2 Inhibitor Highly Effective in Preclinical Lung Cancer Models. Oncogene, 27, 4702-4711. https://doi.org/10.1038/onc.2008.109
[13]
Xie, H., Lin, L., Tong, L., Jiang, Y., Zheng, M., Chen, Z., Jiang, X., et al. (2011) AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both in Vitro and in Vivo. PLoS ONE, 6, e21487. https://doi.org/10.1371/journal.pone.0021487
[14]
Takeda, M. and Nakagawa, K. (2017) Toxicity Profile Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Epidermal Growth Factor Receptor Gene Mutation-Positive Lung Cancer (Review). Molecular and Clinical Oncology, 6, 3-6. https://doi.org/10.3892/mco.2016.1099
[15]
Klutchko, S.R., Zhou, H.R., Winters, T., Tran, T.P., Bridges, A.J., Althaus, I.W., et al. (2006) Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]Pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors. Journal of Medicinal Chemistry, 49, 1475-1485.
https://doi.org/10.1021/jm050936o
[16]
Barf, T. and Kaptein, A. (2012) Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. Journal of Medicinal Chemistry, 55, 6243-6262. https://doi.org/10.1021/jm3003203
[17]
Yoshida, Y., Ozawa, T., Yao, T.W., Shen, W., Brown, D., Parsa, T.A., Raizer, J.J., et al. (2014) NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. Molecular Cancer Therapeutics, 13, 2919-2929. https://doi.org/10.1158/1535-7163.MCT-14-0306
[18]
Ahmed, M., Sadek, M.M., Abouzid, K.A. and Wang, F. (2013) In Silico Design: Extended Molecular Dynamic Simulations of New Series of Dually Acting Inhibitors against EGFR and HER2. Journal of Molecular Graphics and Modelling, 44, 220-231. https://doi.org/10.1016/j.jmgm.2013.06.004
[19]
Gogoi, D., Baruah, V.J., Chaliha, A.K. and Buragohain, A.K. (2016) 3D Pharmacophore-Based Virtual Screening, Docking and Density Functional Theory Approach towards the Discovery of Novel Human Epidermal Growth Factor Receptor-2 (HER2) Inhibitors. Journal of Theoretical Biology, 411, 68-80.
https://doi.org/10.1016/j.jtbi.2016.09.016
[20]
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Advanced Drug Delivery Reviews, 46, 3-26. https://doi.org/10.1016/S0169-409X(00)00129-0
[21]
Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry, 45, 2615-2623.
https://doi.org/10.1021/jm020017n
[22]
Tian, S., Wang, J., Li, Y., Li, D., Xu, L. and Hou, T. (2015) The Application of in Silico Drug Likeness Predictions Pharmaceutical Research. Advanced Drug Delivery Review, 86, 2-10.
https://doi.org/10.1016/j.addr.2015.01.009
[23]
Zou, Y., Xiao, J., Tu, Z., Zhang, Y., Yao, K., Luo, M., Ding, K., et al. (2016) Structure-Based Discovery of Novel 4,5,6-Trisubstituted Pyrimidines as Potent Covalent Bruton’s Tyrosine Kinase Inhibitors. Bioorganic and Medicinal Chemistry Letters, 26, 3052-3059. https://doi.org/10.1016/j.bmcl.2016.05.014
[24]
Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., et al. (2015) GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
[25]
Berendsen, H.J.C., Vanderspoel, D. and Vandrunen, R. (1995) GROMACS: A Message-Passing Parallel Molecular Dynamics Implementation. Computer Physics Communications, 91, 43-56.
https://doi.org/10.1016/0010-4655(95)00042-E
[26]
Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J.L., Dror, R.O., et al. (2010) Improved Side-Chain Torsion Potentials for the Amber ff99SB Protein Force Field. Proteins-Structure Function and Bioinformatics, 78, 1950-1958. https://doi.org/10.1002/prot.22711
[27]
Case, D.A., Cerutti, D.S., III, T.E.C., Darden, T.A., Duke, R.E, T.J., et al. (2017) AMBER16 and AmberTools17. University of California, San Francisco.
[28]
Wang, J.M., Wolf, R.M., Caldwell, J.W., Kollman, P.A. and Case, D.A. (2004) Development and Testing of a General Amber Force Field. Journal of Computational Chemistry, 25, 1157-1174.
https://doi.org/10.1002/jcc.20035
[29]
Cheng, F., Li, W., Zhou, Y., et al. (2012) admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties. Journal of Chemical Information and Modeling, 52, 3099-3105.
https://doi.org/10.1021/ci300367a
[30]
Levit, A., Yarnitzky, T., Wiener, A., Meidan, R. and Niv, M.Y. (2011) Modeling of Human Prokineticin Receptors: Interaction with Novel Small-Molecule Binders and Potential Off-Target Drugs. PLoS ONE, 6, e27990. https://doi.org/10.1371/journal.pone.0027990
[31]
Vyas, V.K., Goel, A., Ghate, M. and Patel, P. (2015) Ligand and Structure-Based Approaches for the Identification of SIRT1 Activators. Chemico-Biological Interactions, 228, 9-17. https://doi.org/10.1016/j.cbi.2015.01.001
[32]
Güner, O.F. and Henry, D.R. (2000) Metric for Analyzing Hit Lists and Pharmacophores. In: Güner, O.F., Ed., IUL Biotechnology Series, 191-212.
[33]
Güner, O.F., Waldman, M., Hoffmann, D. and Kim, J.H. (2000) Strategies for Database Mining and Pharmacophore Development, 1st Edition. In: Güner, O.F., Ed., Pharmacophore Perception, Development, and Use in Drug Design, IUL Biotechnology Series, 213-236.
[34]
Kumar, S.P. and Jha, P.C. (2016) Multi-level Structure-Based Pharmacophore Modelling of Caspase-3-Non-Peptide Complexes: Extracting Essential Pharmacophore Features and Its Application to Virtual Screening. Chemico-Biological Interactions, 254, 207-220. https://doi.org/10.1016/j.cbi.2016.06.011
[35]
Lu, S.H., Wu, J.W., Liu, H.I., Zhao, J.H., Liu, K.T., Chuang, C.K., Lin, H.Y., Tsai, W.B. and Ho, Y. (2011) The Discovery of Potential Acetylcholinesterase Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies. Journal of Biomedical Science, 18, Article ID: 23244.
https://doi.org/10.1186/1423-0127-18-8
[36]
Thangapandian, S., John, S., Sakkiah, S. and Lee, K.W. (2010) Ligand and Structure Based Pharmacophore Modeling to Facilitate Novel Histone Deacetylase 8 Inhibitor Design. European Journal of Medicinal Chemistry, 45, 4409-4417. https://doi.org/10.1016/j.ejmech.2010.06.024
Swellmeen, L., Shahin, R., Al-Hiari, Y., Alamiri, A., Hasan, A. and Shaheen, O. (2017) Structure-Based Drug Design of Pim-1 Kinase Followed by Pharmacophore Guided Synthesis of Quinolone-Based Inhibitors. Bioorganic and Medicinal Chemistry, 25, 4855-4875. https://doi.org/10.1016/j.bmc.2017.07.036
[39]
Liu, C., He, G., Jiang, Q., Han, B. and Peng, C. (2013) Novel Hybrid Virtual Screening Protocol Based on Molecular Docking and Structure-Based Pharmacophore for Discovery of Methionyl-tRNA Synthetase Inhibitors as Antibacterial Agents. International Journal of Molecular Sciences, 14, 14225-14239.
https://doi.org/10.3390/ijms140714225
[40]
Telesco, S.E. and Radhakrishnan, R. (2009) Atomistic Insights into Regulatory Mechanisms of the HER2 Tyrosine Kinase Domain: A Molecular Dynamics Study. Biophysical Journal, 96, 2321-2334.
https://doi.org/10.1016/j.bpj.2008.12.3912
[41]
Schuler, M., Awada, A., Harter, P., Canon, J.L., Possinger, K., Schmidt, M., et al. (2012) A Phase II Trial to Assess Efficacy and Safety to Afatinib in Extensively Pretreated Patients with HER2-Negative Metastatic Breast Cancer. B Breast Cancer Research and Treatment, 134, 1149-1159. https://doi.org/10.1007/s10549-012-2126-1
[42]
Tamokou, J.D.E. and Kuete, V. (2014) Chap. 10. Mutagenicity and Carcinogenicity of African Medicinal Plants. In: Kuete, V., Ed., Toxicological Survey of African Medicinal Plants, Elsevier, Amsterdam, 277-322.
https://doi.org/10.1016/B978-0-12-800018-2.00010-8
[43]
Huang, S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., et al. (2008) New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. Journal of Clinical Pharmacology, 48, 662-670. https://doi.org/10.1177/0091270007312153
[44]
Sanguinetti, M.C. and Tristani-Firouzi, M. (2006) hERG Potassium Channels and Cardiac Arrhythmia. Nature, 440, 463-469. https://doi.org/10.1038/nature04710
[45]
Wang, S., Li, Y., Wang, J., Chen, L., Zhang, L., Yu, H. and Hou, T. (2012) ADMET Evaluation in Drug Discovery. 12. Development of Binary Classification Models for Prediction of hERG Potassium Channel Blockage. Molecular Pharmaceutics, 9, 996-1010. https://doi.org/10.1021/mp300023x
[46]
Guengerich, F.P. (2008) Cytochrome P450 and Chemical Toxicology. Chemical Research in Toxicology, 21, 70-83. https://doi.org/10.1021/tx700079z
[47]
Tsou, H.R., Mamuya, N., Johnson, B.D., Reich, M.F., Gruber, B.C., Ye, F., et al. (2001) 6-Substituted-4-(3-Bromophenylamino)Quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. Journal of Medicinal Chemistry, 44, 2719-2734.
https://doi.org/10.1021/jm0005555
